Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
31.67
-0.17 (-0.53%)
At close: Sep 12, 2025, 4:00 PM EDT
32.68
+1.01 (3.19%)
Pre-market: Sep 15, 2025, 7:52 AM EDT
Scholar Rock Holding Employees
Scholar Rock Holding had 128 employees as of December 31, 2024. The number of employees decreased by 22 or -14.67% compared to the previous year.
Employees
128
Change (1Y)
-22
Growth (1Y)
-14.67%
Revenue / Employee
n/a
Profits / Employee
-$2,466,305
Market Cap
3.04B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128 | -22 | -14.67% |
| Dec 31, 2023 | 150 | 36 | 31.58% |
| Dec 31, 2022 | 114 | -31 | -21.38% |
| Dec 31, 2021 | 145 | 26 | 21.85% |
| Dec 31, 2020 | 119 | 26 | 27.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SRRK News
- 2 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment - Business Wire
- 5 weeks ago - Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress - Business Wire
- 2 months ago - Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 - Business Wire
- 3 months ago - Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial - Business Wire
- 3 months ago - Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
- 3 months ago - Scholar Rock Shares Jump on Positive Results from Weight Loss Trial - Market Watch